Research

Research Summary: Evaluating the safety of β-interferons in MS Research from the University of British Columbia has looked at the long-term health effects of interferon-beta treatment in people with...

There has been a lot of media attention recently on a trial testing statins as a treatment for multiple sclerosis (MS).  The study is being led by University College London and will involve over 1100 people...

What is laquinimod? Laquinimod is a once-daily oral medication that has been developed and tested for the treatment of relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS). The...

Research Summary: An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event An increasing emphasis is being placed on how lifestyle...

In one of our recent Facebook Live Q&A sessions, I was asked what I thought the biggest hurdle was that needed to be overcome in multiple sclerosis research.  Whilst funding problems are something that we...

Research Summary: Rab32 connects ER stress to mitochondrial defects in multiple sclerosis Mitochondria are often referred to as the ‘powerhouses’ of the cell, as they are largely responsible for the...

Research Summary: Regulatory T cells promote myelin regeneration in the central nervous system When we think about treating multiple sclerosis, generally there are two main approaches that are discussed. ...

Imagine you have a dog and a cat and they keep fighting. Solution 1: give one of your pets to someone else. Solution 2: Teach them to get along. Solution 1 describes almost all current MS...

Research Summary: Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression A recent Australian research breakthrough in multiple sclerosis (MS) has drawn...

Research Summary: High dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS The 5 year results of the HALT-MS trial were today published in Neurology.  The HALT-MS clinical trial has...